Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px
Document › Details

ThromboGenics N.V.. (1/26/18). "Press Release: Novartis Pharma AG Holding 5.69% of ThromboGenics Equity Capital". Leuven.

Organisations Organisation ThromboGenics N.V. (Euronext Brussels: THR)
  Today Oxurion N.V. (Euronext Brussels: OXUR)
  Group Oxurion (Group)
  Organisation 2 Novartis Pharma AG
  Group Novartis (Group)
Products Product Jetrea®
  Product 2 ophthalmic
Index terms Index term ThromboGenics–Novartis: investment, 201709–201801 equity investment €10m by Novartis after termination of Jetrea agreement
  Index term 2 Novartis–ThromboGenics: ocriplasmin, 201203– 201709 commercialisation rights for Jetrea outside US to Alcon €75m upfront + €300m ms TERMINATED 9/17
Person Person Clay, Thomas (ThromboGenics 201706– Board Chairman joined as Non-executive Board Member 2011)
     


Pursuant to Belgian transparency legislation (Law of 2 May 2007), ThromboGenics NV (Euronext Brussels: THR) received a transparency notification on 26 January 2018 from Novartis Pharma AG (‘Novartis’).

Novartis notified that, on 26 January 2018, the ThromboGenics shares controlled by Novartis are 2,177,226 shares, or 5.69% of the current 38,271,575 outstanding ThromboGenics shares.

ThromboGenics has issued 2,177,226 new ordinary shares to Novartis, increasing its number of outstanding shares to 38,271,575. This capital increase was approved at the Extra-ordinary Shareholders Meeting of 20 November 2017.

Novartis subscribed for newly issued shares at a price of €4.593 per share, corresponding with the average of the trading price calculated during the 30 days preceding approval on 20 November 2017.

On 26 January 2018, based on all received transparency declarations received, ThromboGenics NV is aware of the following participations:

Shareholder
number of securities
% of voting rights

Mr Thomas M. Clay and entities controlled by him
3,361,555
8.78%

Baron Philippe Vlerick and entities controlled by him
2,324,719
6.07%

Novartis Pharma AG
2,177,226
5.69%


For further information please contact:

ThromboGenics
Wouter Piepers, Global Head of Corp Coms & Investor relations
+32 16 75 13 10 / +32 478 33 56 32
wouter.piepers@thrombogenics.com

Citigate Dewe Rogerson
David Dible/ Sylvie Berrebi/ Isabelle Andrews
Tel: +44 20 7638 9571 thrombogenics@citigatedewerogerson.com


About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for eye disease, with a focus on diabetic eye disease. The company’s pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.

ThromboGenics’ is currently evaluating THR-317, a PLGF inhibitor in a Phase I/IIa clinical study for the treatment of diabetic macular edema. Results are expected in Q1 2018. ThromboGenics’ late pre-clinical pipeline consists of THR-149, a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, an integrin antagonist, which was in-licensed from Galapagos. THR-149 is expected to enter the clinic in the first half of 2018 and THR-687 around mid-2018. Further new drug candidates are currently being progressed for the treatment of diabetic eye disease and one of these is expected to enter development in 2018.

ThromboGenics owns the global rights to JETREA® (ocriplasmin), the only pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the US) and vitreomacular traction (in Europe and elsewhere).

ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR.

More information is available at www.thrombogenics.com


Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forwardlooking statement is contained in the Company’s Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

   
Record changed: 2018-09-15

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for Oxurion (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px




» top